BridgeBio Pharma, Inc. Balance Sheet
BBIO / Health Care|9 years of annual SEC 10-K data (FY2017-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 9 fiscal years. All figures from audited SEC 10-K filings.
BridgeBio Pharma, Inc. had $936M in total assets with negative shareholders' equity of $2.1B as of FY2025. Total debt was $2.0B against $570M in cash, resulting in $1.4B net debt.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $570.1M | $681.1M | $376.7M | $376.7M | $356.1M | $356.1M | $363.8M | $436.1M | $92.0M |
| Accounts Receivable | $139.4M | $4.7M | - | - | - | - | - | - | - |
| Inventory | $26.8M | $0 | - | - | - | - | - | - | - |
| Current Assets | $797.7M | $720.7M | $477.6M | $548.9M | $888.9M | $642.8M | $568.6M | $445.2M | - |
| PP&E (Net) | $5.4M | $7.0M | $11.8M | $14.6M | $30.1M | $20.3M | $5.6M | $1.6M | - |
| Total Assets | $936.0M | $919.3M | $546.4M | $623.0M | $1.0B | $703.6M | $631.7M | $464.9M | - |
| Current Liabilities | $288.0M | $154.4M | $143.8M | $121.4M | $135.1M | $95.6M | $60.4M | $32.6M | - |
| Total Debt | $2.0B | $437.3M | $446.4M | $431.0M | $430.8M | $93.9M | $95.4M | $54.5M | - |
| Shareholders' Equity | -$2.1B | -$1.5B | -$1.4B | -$1.3B | -$870.4M | $57.9M | $408.5M | $377.2M | $88.3M |